<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 C:\PWang\Datasets\grobid-0.5.5\grobid-0.5.5\grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.5.5" ident="GROBID" when="2020-06-22T14:02+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2012-07-24">Available online 24 July 2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Tomá S Tichý</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Organic Chemistry and Biochemistry</orgName>
								<orgName type="institution">Academy of Sciences of the Czech Republic, v.v.i</orgName>
								<address>
									<addrLine>Flemingovo nám. 2</addrLine>
									<postCode>166 10</postCode>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Graciela</forename><surname>Andrei</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Rega Institute for Medical Research</orgName>
								<orgName type="institution" key="instit2">Katholieke Universiteit Leuven</orgName>
								<address>
									<addrLine>Minderbroedersstraat 10</addrLine>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Snoeck</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Rega Institute for Medical Research</orgName>
								<orgName type="institution" key="instit2">Katholieke Universiteit Leuven</orgName>
								<address>
									<addrLine>Minderbroedersstraat 10</addrLine>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><surname>Balzarini</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Rega Institute for Medical Research</orgName>
								<orgName type="institution" key="instit2">Katholieke Universiteit Leuven</orgName>
								<address>
									<addrLine>Minderbroedersstraat 10</addrLine>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Dra</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Organic Chemistry and Biochemistry</orgName>
								<orgName type="institution">Academy of Sciences of the Czech Republic, v.v.i</orgName>
								<address>
									<addrLine>Flemingovo nám. 2</addrLine>
									<postCode>166 10</postCode>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marcela</forename><surname>Kre Cmerová</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Organic Chemistry and Biochemistry</orgName>
								<orgName type="institution">Academy of Sciences of the Czech Republic, v.v.i</orgName>
								<address>
									<addrLine>Flemingovo nám. 2</addrLine>
									<postCode>166 10</postCode>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2012-07-24">Available online 24 July 2012</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1016/j.ejmech.2012.07.027</idno>
					<note type="submission">Article history: Received 14 March 2012 Received in revised form 12 July 2012 Accepted 17 July 2012</note>
					<note>Original article a r t i c l e i n f o</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<textClass>
				<keywords>Antivirals Prodrugs Acyclic nucleoside phosphonate Phosphonate ester In vitro evaluation</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>a b s t r a c t</head><p>Hexadecyloxypropyl esters of acyclic nucleoside phosphonates containing guanine (G) or hypoxanthine (Hx) and a (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] [(S)-HPMP] or 2-(2-phosphonoethoxy)ethyl (PEE) acyclic moiety have been prepared. The activity of the prodrugs was evaluated in vitro against different virus families. Whereas ester derivatives of PEEHx and (S)-HPMPHx were antivirally inactive, monoesters of PEEG, and mono-and diesters of (S)-HPMPG showed pronounced antiviral activity against vaccinia virus and/or herpesviruses. Monoesters of (S)-HPMPG emerged as the most potent and selective derivatives against these DNA viruses. None of the compounds were inhibitory against RNA viruses and retroviruses.</p><p>Crown</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Acyclic nucleoside phosphonates <ref type="bibr" target="#b0">[1]</ref> constitute a group of compounds with a wide range of biological activities including antiviral, cytostatic, antiparasitic and immunomodulatory effects. The compounds with guanine or hypoxanthine as a nucleobase bearing (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] [(S)-HPMP], or 2-(2-phosphonoethoxy)ethyl (PEE) chain have been reported as potential antimalarial agents <ref type="bibr" target="#b1">[2]</ref> capable to inhibit the 6-oxopurine phosphoribosyltransferase <ref type="bibr" target="#b2">[3]</ref> of the Plasmodium parasite. In order to increase membrane permeability of above mentioned phosphonates, we have masked the ionic character of the drugs using the Hostetler's prodrug strategy <ref type="bibr" target="#b3">[4]</ref> and hexadecyloxypropyl esters of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine [(S)-HPMPG], 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]hypoxanthine [(S)-HPMPHx], 9-[2-(phosphonomethoxy)ethyl]guanine (PEEG) and 9-[2-(phosphonomethoxy)ethyl]hypoxanthine (PEEHx) have been prepared. Their activities against Plasmodium are the subject of another study <ref type="bibr" target="#b4">[5]</ref>. Herein we focus on their antiviral activities against various virus strains. Among the parent drugs, (S)-HPMPG has been reported <ref type="bibr" target="#b5">[6]</ref> as an active compound against herpes simplex virus (HSV) type 1 and type 2, varicella-zoster virus (VZV), cytomegalovirus <ref type="bibr">(CMV)</ref> and vaccinia virus (EC 50 in the mM range). The octadecyloxyethyl ester of (S)-HPMPG, a close analog of prodrug 16 in this study, has been reported <ref type="bibr" target="#b6">[7]</ref> to display enhanced antiviral activity compared to the parent drug. Attachment of a highly lipophilic hexadecyloxypropyl moiety increases the cellular permeability as well as antiviral activities of the prodrug, probably due to the greater availability for cellular phosphorylation <ref type="bibr" target="#b3">[4]</ref>. Thus strong antiviral activities of hexadecyloxypropyl esters of (S)-HPMPG against DNA virus strains can be expected. Also drugs previously found to be weakly active (PEEG) may show more pronounced activity after their conversion to hexadecyloxypropyl esters. Additionally, the structureeactivity relationship among various prodrug types (diester, monoester, cyclic monoester) is reported below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Results and discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Chemistry</head><p>For alkylation of the phosphonate function with the hexadecyloxypropyl moiety, we considered two approaches using PEEG as a model compound. The first is a broadly used methodology <ref type="bibr" target="#b7">[8]</ref> involving in situ preparation of a bis chloridate followed by subsequent reaction with hexadecyloxypropyl alcohol in the presence of a base. The latter approach <ref type="bibr" target="#b8">[9]</ref> involves neutralization of the phosphonate function with tetrabutylammonium hydroxide followed by nucleophilic reaction of the resulting phosphonate salt with hexadecyloxypropyl bromide. However, both methodologies afforded low yields of PEEG esters (&lt;10%) due to the low conversion and the simultaneous alkylation of nucleobase. In order to circumvent these problems,we alkylated the acyclic phosphonate synthon which was subsequently coupled with an appropriate nucleobase. For the preparation of PEEG and PEEHx prodrugs, bis isopropyl phosphonoethoxyethylchloride <ref type="bibr" target="#b9">[10]</ref> 1 was transformed to the free phosphonic acid and subsequently to bis chloridate which was treated with hexadecyloxypropyl alcohol in the presence of pyridine and triethylamine. Bis hexadecyloxypropyl ester 2 was isolated in high yield. The nucleophilic substitution reaction of alkylated phosphonate synthon with 6-chloropurine or 2-amino-6-chloropurine in the presence of Cs 2 CO 3 as a base followed by acid catalyzed cleavage of the 6-chloro substituent afforded bis hexadecyloxypropyl esters of PEEG or PEEHx. Appropriate monoesters 5 and 6 were prepared by dissolving diesters 3 and 4 in DMF and heating in the presence of a nucleophilic agent (LiN 3 ) causing removal of one alkyl ester group <ref type="bibr" target="#b10">[11]</ref> (Scheme 1).</p><p>Similar to the preparation of PEEG and PEEHx prodrugs, the preparation of (S)-HPMPG and (S)-HPMPHx prodrugs began with the conversion of bis isopropyl phosphonomethyltosylate 7 to bis(hexadecyloxypropyl) phosphonomethyltosylate 8 <ref type="bibr" target="#b11">[12]</ref>. The alkylated phosphonate synthon was coupled with pre-prepared 9-(2-hydroxy-3-trityloxypropyl)-6-O-benzylpurine 11 or 9-(2-hydroxy-3-trityloxypropyl)-2-amino-6-O-benzylpurine 12 in the presence of a base (NaH). Pre-preparation involved nucleophilic opening of the oxirane ring of (S)-(À)-glycidol trityl ether with 6-Obenzylpurine 9 or 2-amino-6-O-benzylpurine 10. The acid labile protective groups (OBn, OTr) of the resulting adducts were cleaved by the action of HCl. The diesters 13 and 14 were hydrolyzed in a solution of NaOH giving monoesters 15 and 16. Above mentioned method <ref type="bibr" target="#b10">[11]</ref> using milder conditions resulted in incomplete conversion in this case. Intramolecular esterification of 15 and 16 mediated by PyBOP <ref type="bibr" target="#b12">[13]</ref> afforded cyclic hexadecyloxypropyl esters 17 and 18 as a mixture of diastereomers (1:1 ratio according to the NMR spectra) (Scheme 2).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Biological activities</head><p>Esterification of acyclic nucleoside phosphonates such as (S)-HPMPC and (S)-HPMPA with various alkoxyalkyl or alkylglycerol groups has been shown to result in remarkable increases in antiviral activities against herpesviruses and poxviruses <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>. The rationale behind this study was to demonstrate whether enhanced lipophilicity of (S)-HPMPG, (S)-HPMPHx, PEEG and PEEHx correlates with increased antiviral activity. For that purpose, hexadecyloxypropyl diesters, monoesters and cyclic monoesters of these compounds were prepared and their antiviral properties were evaluated in vitro.</p><p>The antiviral activity of the different compounds was evaluated against various DNA viruses, including poxviruses [i.e. vaccinia virus (VACV)], herpesviruses [i.e. herpes simplex virus type 1 (HSV-1)] and type 2 (HSV-2), thymidine kinase-deficient HSV-1 (acyclovir-resistant, ACV r ), varicella-zoster virus (VZV), and human cytomegalovirus (HCMV) ( <ref type="table" target="#tab_0">Table 1)</ref>, and retroviruses including human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2). All compounds were also examined against several RNA viruses, including vesicular stomatitis virus (VSV), Coxsackie B4 virus, respiratory syncytial virus (RSV), parainfluenza virus type 3, reovirus-1, Sindbis virus and Punta Toro virus. None of the prodrugs showed activity against any of the RNA viruses nor retroviruses tested.</p><p>Similar to the parent compound, both the diester and monoester prodrugs of PEEHx (i.e. compounds 3 and 5) proved inactive against herpesviruses and poxviruses. Although the diester prodrug of PEEG (compound 4) lacked also activity against these DNA viruses, the monoester derivative (compound 6) was able to potently inhibit the replication of VZV, HSV and HCMV at EC 50 values in the range of, respectively, 0.14e0.30 mM, 1.4e2.8 mM, and 0.06e0.13 mM. Since compound 6 inhibited cell growth at a CC 50 (50% cytostatic concentration) value of 26 mM, selectivity indices (ratio CC 50 to EC 50 ) ranged from 9 to 433 depending on the nature of the virus. Interestingly, compound 6 was inactive against feline herpesvirus and against VACV.</p><p>Among the HPMP prodrugs, attachment of highly lipophilic hexadecyloxypropyl moieties to (S)-HPMPHx did not result in an increase of the antiviral activity since compounds 15 (monoester), 13 (diester) and 17 (cyclic monoester) were totally inactive against herpesviruses and poxviruses.</p><p>The diester derivative of (S)-HPMPG (compound 14) showed EC 50 values that were 7-fold (VZV and HCMV), 15-to 40-fold (HSV), 157-fold (feline herpesvirus) and 41-fold (VACV) lower than those for the parent compound. However, the monoester and cyclic monoester derivatives of (S)-HPMPG proved more active and selective than the diester derivative. This observation supports previous assumption <ref type="bibr" target="#b3">[4]</ref> that the phosphonate double-ester prodrugs penetrate the cell membrane less rapidly than their monoester counterpairs, even in case an ionized phosphonate group is present in the monoester prodrug. Thus, compound 16 (monoester) and compound 18 (cyclic monoester) inhibited VZV replication with EC 50 values in the range of 0.001e0.0025 mM for VZV, 0.007e0.09 mM for HSV, and 0.002e0.007 mM for HCMV. While the monoester derivative of (S)-HPMPG was inactive against feline herpesvirus, the cyclic monoester derivative was able to inhibit viral replication with an EC 50 of 0.43 mM. However, compound 16 proved more active than compound 18 against VACV (EC 50 ¼ 0.011 mM for compound 16 compared to 0.13 mM for compound 18). As the monoester derivative of (S)-HPMPG (compound 16) proved significantly more cystostatic than the cyclic monoester (compound 18) with a CC 50 of 0.72 mM and 19 mM, respectively, SIs were 2-to 66-fold lower for compound 16 compared to compound 18. Thus, the cyclic monoester of (S) HPMPG showed the high selectivity among all the prodrug tested with SIs in the range of 2700e19,000 for VZV, 211e559 for HSV, 3800e9500 for HCMV, and 146 for VACV.</p><note type="other">Scheme</note><p>Our data show that enhanced lipophilicity of (S)-HPMPG resulted in increased antiviral activity and selectivity in vitro against herpesviruses and poxviruses. The significant gain in antiviral activity and selectivity for compound 18 compared to the parent compound can be explained in a similar way as for other ANPs, i.e. increased cellular uptake of the ester deriatives, more rapid conversion to the diphosphate active forms and also metabolic stability of the ester derivatives. Even compounds, such as 6 and 16, that are charged in physiological conditions are able to penetrate the cell membrane since they presented significant antiviral activity. Antimicrobial activities (Bordetella pertusis, Bacillus anthracis) of the prodrugs will be also tested.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Conclusion</head><p>Hexadecyloxypropyl diesters, monoesters and cyclic monoesters of (S)-HPMPG, (S)-HPMPHx, PEEG and PEEHx have been prepared and their antiviral properties were evaluated in vitro.</p><p>None of the hexadecyloxypropyl esters of (S)-HPMPHx nor PEEHx proved active against herpesviruses and poxviruses. Although the hexadecyloxypropyl diester of PEEG was antivirally inactive, the monoester derivative gained activity against herpesviruses. Attachment of highly lipophilic hexadecyloxypropyl moieties to (S)-HPMPG resulted in improvement of its antiviral activity against herpesviruses. The cyclic monoester derivative of (S)-HPMPG emerged as the most selective antiviral compound.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Experimental</head><p>Unless stated otherwise, solvents were evaporated at 40 C and compounds were dried at 100 Pa. The purification of the products by reverse phase HPLC was performed on a Waters Delta 600 instrument with a Waters 2487 Dual l Absorbance Detector using Luna Phe- C at 125.7 MHz). The spectra were referenced to TMS or dioxane (d 3.75 and 67.19) as internal standards or to the residual solvent signal (d 2.50 and 39.7 for DMSO). Mass spectra were measured by the ESI technique using LCQ Fleet or LTQ Orbitrap XL (Thermo Fisher Scientific). Most of the chemicals and ion-exchange resins were purchased from SigmaeAldrich (Czech Republic). The general numbering for the assignment of the NMR signals is depicted below <ref type="figure" target="#fig_0">(Fig. 1).</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">General method A</head><p>Bis isopropyl phosphonoethoxyethylchloride (1) (2.58 g, 10.0 mmol) or bis isopropyl phosphonomethyltosylate (7) (3.50 g, 10.0 mmol) in anhydrous acetonitrile (130 ml) was treated with  bromotrimethylsilane (13 ml) overnight at room temperature. The mixture was then evaporated and codistilled with acetonitrile (3 Â 25 mL), water (2 Â 25 ml), ethanol (25 mL) and toluene (3 Â 25 mL). The syrupy residue was dissolved in dichloromethane (50 ml) then DMF (0.1 ml) and oxalyl chloride (6.0 ml, 68.8 mmol) were added. The solution was gently refluxed (2 h), evaporated to dryness, and redissolved in dichloromethane (20 ml). The solution was cooled down to 0 C and treated slowly with pyridine (1.6 ml). The mixture was added to a cooled (À30 C) solution of hexadecyloxypropanol (6.01 g, 20 mmol) in dichloromethane (100 ml) and triethylamine (8.7 ml). The mixture was allowed to reach 0 C and kept at this temperature for 3 h. The reaction mixture was evaporated, codistilled with toluene (3 Â 50 ml) and the residue was chromatographed on a silica gel column (400 g) in EtOAc/hexane (1:2 / 1:1).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.1.">Bis(hexadecyloxypropyl)phosphonoethoxyethylchloride (2)</head><p>Yield 6.50 g of syrup (88%). The crude product was used without further purification procedures. ESI-MS, m/z: 753. <ref type="bibr">6 (53)</ref>  </p><formula xml:id="formula_0">[M þ H] þ , 775.6 (100) [M þ Na] þ , 791.5 (22) [M þ K] þ ,</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.2.">Bis(hexadecyloxypropyl)phosphonomethyltosylate (8)</head><p>Prepared similarly according to the published procedure <ref type="bibr" target="#b11">[12]</ref>. Yield 6.94 g of syrup (83%). Identity was verified using authentic sample on TLC, R f w0.3 (30% EtOAc/hexane).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">General method B</head><p>The mixture of 6-chloropurine or 2-amino-6-chloropurine (1.5 mmol, 232 or 254 mg, respectively), bis (hexadecyloxypropyl) phosphonoethoxyethylchloride (754 mg, 1.0 mmol), Cs 2 CO 3 (326 mg, 1.0 mmol) and DMF (10 ml) was heated to 100 C for 6 h (reaction with aminochloropurine) or 16 h (reaction with chloropurine). The mixture was evaporated and the residue was chromatographed on a silica gel column (50 g) in 6% MeOH/CHCl 3 . The crude product was refluxed in 80% aqueous acetic acid for 2 h, then concentrated and chromatographed on a silica gel column (30 g) in 7% MeOH/CHCl 3 .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.1.">Bis 3-(hexadecyloxypropyl) ester of 9-[2-(phosphonomethoxy)ethyl]hypoxanthine (3)</head><p>Yield 285 mg (33%  </p><formula xml:id="formula_1">868.7 (100) [M þ H] þ , 890.6 (77) [M þ Na] þ , 906.6 (20) [M þ K] þ .</formula><p>ESI  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.">General method C</head><p>The mixture of 3 or 4 (0.2 mmol, 170 mg or 174 mg respectively) and LiN 3 (1.6 mmol, 78 mg) in DMF (2 ml) was heated to 100 C for 16 h and then evaporated. The syrupy residue was chromatographed on a silica gel column in MeOH/CHCl 3 (20% / 40%). The combined fractions containing product were evaporated and dissolved in hot water (2 ml, drop of 10% aqueous ammonia was added for complete dissolution). The solution was neutralized with aqueous hydrochloric acid to pH z 3. Crystallized product was filtered off and washed with water.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.1.">3-(Hexadecyloxypropyl) ester of 9-[2-(phosphonomethoxy) ethyl]hypoxanthine (5)</head><p>Yield: 73 mg (64%). Mp 90e92 C. Anal. Calcd for C 28 H 52 N 4 O 6.5 P (hemihydrate): C, 58.01; H, 9.04; N, 9.66; P, 5.34. Found: C, 58.19; H, 9.04; N, 9.41; P, 5.14. ESI-MS, m/z: 571. <ref type="bibr">4 (89)</ref>      </p><formula xml:id="formula_2">[M þ H] þ , 593.4 (100) [M þ Na] þ , 609.3 (62) [M þ K] þ ,</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.">General method D</head><p>A mixture of 6-O-benzylpurine (9) or 2-amino-6-O-benzylpurine (10) (20 mmol, 4.52 g or 4.82 g, respectively), S-(À)-glycidol trityl ether (6.33 g, 20 mmol), Cs 2 CO 3 (800 mg, 2.5 mmol) in DMF (100 ml) was heated to 100 C for 10 h. The solution was evaporated and the syrupy residue was chromatographed on a silica gel column (500 g) in EtOAc/toluene (1:3). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.">General method E</head><p>A mixture of 11 or 12 (2.4 mmol, 1.30 g or 1.34 g respectively) and 8 (2.66 g, 3.6 mmol) in anhydrous DMF (20 ml) was treated with NaH (60% suspension in mineral oil, 290 mg, 7.2 mmol) while cooling down (À25 C). The mixture was stirred at a room temperature overnight and then heated to 35 C for 8 h. The mixture was then neutralized with acetic acid (0.27 ml, 4.8 mmol) and partitioned between chloroform (100 ml) and aqueous saturated solution of NaCl (100 ml). The aqueous portion was extracted with chloroform again (50 ml). The combined organic portions were dried with MgSO 4 evaporated and the syrupy residue was chromatographed on a silica gel column (200 g) in gradient EtOAc/toluene (1:1) / EtOAc. Syrupy trityl derivative was dissolved in Et 2 O/MeOH (1:1, 10 ml). The solution was acidified with methanolic solution of hydrogen chloride to pH 2e3 and stirred for 48 h. The product crystallized overnight in a fridge. The mother liquors were concentrated and chromatographed on a silica gel column in methanol/chloroform/hexane (1:5:5).     </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.">General method F</head><p>To a solution of 13 or 14 (0.5 mmol, 435 mg or 442 mg, respectively) in dioxane (25 ml) an aqueous solution of NaOH (2M, 0.5 ml, 1.0 mmol) was added and the mixture was stirred for 48 h. The solution was neutralized with hydrochloric acid (1 M, 1.1 ml, 1.1 mmol). Mixture was evaporated, codistilled with toluene and the residue was chromatographed on a silica gel column (20 g) in methanol/chloroform (1:4 / 1:2). </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>1 .</head><label>1</label><figDesc>Scheme 1. The preparation of prodrugs 3e6. Reagents and conditions: (a) Me 3 SiBr, MeCN, r.t., then H 2 O; (b) (COCl) 2 , DMF, CH 2 Cl 2 , 40 C; (c) pyridine, 0 C, then hexadecyloxypropyl alcohol, Et 3 N, CH 2 Cl 2 , À30 C / 0 C; (d) 6-chloropurine or 2-amino-6-chloropurine, Cs 2 CO 3 , DMF, 100 C; (e) AcOH, H 2 O, reflux; (f) LiN 3 , DMF, 100 C.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>nomenex Ò C-18 preparative columns (10 mm, 21 Â 250 mm, flow 12 ml/min); the elution conditions are given in the text. The column chromatography was performed on 60 mm silica gel (Fluka)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Scheme 2 .</head><label>2</label><figDesc>Scheme 2. The preparation of prodrugs 13e18. The reagents and conditions: (a) Me 3 SiBr, MeCN, r.t., then H 2 O; (b) (COCl) 2 , DMF, CH 2 Cl 2 , 40 C; (c) pyridine, 0 C, then hexadecyloxypropyl alcohol, Et 3 N, CH 2 Cl 2 , À30 C / 0 C; (d) (S)-(À)-glycidol trityl ether, CsCO 3 , DMF, 100 C; (e) NaH, DMF, À25 C / 35 C; (f) HCl, MeOH, Et 2 O, r.t.; (g) NaOH, H 2 O, dioxane, r.t.; (h) PyBOP, i-Pr 2 EtN, DMF, r.t.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc>3 , ppm) d: 13.88 (C-23 0 ), 22.39 (C-22 0 ), 25.87 (C-10 0 ), 26.18 (d, J 4 0 eP ¼ 139.8, C-4 0 ), 29.06, 29.24, 29.33, 29.35, 29.39, 29.40, 29.43 (C- 9 0 , C-11 0 to C-20 0 ), 30.56 (d, J 6 0 eP ¼ 6.3, C-6 0 ), 31.62 (C-21 0 ), 43.93 (C-1 0 ), 62.75 (d, J 5 0 eP ¼ 6.4, C-5 0 ), 64.87 (C-3 0 ), 66.21 (C-7 0 ), 68.24 (C-2 0 ), 70.91 (C-8 0 ),121.90 (C-5),140.07 (C-8),145.84 (C-2),147.76 (C-4),156.09 (C-6). 4.2.2. Bis 3-(hexadecyloxypropyl) ester of 9-[2- (phosphonomethoxy)ethyl]guanine (4) Yield 460 mg (52%). Crystallization from hexane. Mp 130e132 C. Anal. Calcd for C 47 H 90 N 5 O 7 P: C, 65.02; H, 10.45; N, 8.07; P, 3.57. Found: C, 64.69; H, 10.37; N, 7.94; P, 3.48. ESI-MS, m/z:</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>13 C</head><label>13</label><figDesc>NMR (CDCl 3 , ppm) d: 14.10 (C-23 0 ), 22.67 (C-22 0 ), 26.16 (C-10 0 ), 26.38 (d, J 4 0 eP ¼ 140.7, C-4 0 ), 29.35, 29.53, 29.63, 29.65, 29.68, 29.69, 29.71 (C-9 0 , C-11 0 to C-20 0 ), 30.83 (d, J 6 0 eP ¼ 6.3, C-6 0 ), 31.91 (C-21 0 ), 43.22 (C-1 0 ), 63.25 (d, J 5 0 eP ¼ 6.6, C-5 0 ), 64.98 (d, J 3 0 eP ¼ 2.6, C-3 0 ), 66.49 (C-7 0 ), 68.90 (C-2 0 ), 71.22 (C-8 0 ), 115.93 (C-5), 138.04 (C-8), 151.03 (C-4), 154.30 (C-2), 158.05 (C-6).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc>NaOD, ppm) d: 0.90 (t, 3H, J 23 0 e22 0 ¼ 7.1), 1.24e1.35 (m, 26H, H-10 0 to H-22 0 ), 1.53 (m, 2H, H-9 0 ), 1.79e1.87 (m, 4H, H-4 0 , H-6 0 ), 3.37 (t, 2H, J 8 0 e9 0 ¼ 6.9, H-8 0 ), 3.47 (t, 2H, J 7 0 e6 0 ¼ 6.5, H-7 0 ), 3.60 (m, 2H, H-3 0 ), 3.72 (t, 2H, J 2 0 e1 0 ¼ 5.1, H-2 0 ), 3.83 (q, 2H, J 5 0 e6 ¼ J 5 0 eP ¼ 6.6, H-5 0 ), 4.19 (br t, 2H, J 1 0 e2 0 ¼ 5.1, H-1 0 ), 7.88 (s, H-8), 8.01 (s, H-2). 13 C NMR (D 2 O þ NaOD, ppm) d: 14.57 (C-23 0 ), 23.31 (C-22 0 ), 26.65 (C- 10 0 ), 27.79 (d, J 4 0 eP ¼ 131.5, C-4 0 ), 29.98, 30.15, 30.27, 30.48, 30.52, 30.56, 30.59, 30.61 (C-9 0 , C-11 0 to C-20 0 ), 31.14 (d, J 6 0 eP ¼ 6.3, C-6 0 ), 32.64 (C-21 0 ), 43.79 (C-1 0 ), 61.89 (d, J 5 0 eP ¼ 5.6, C-5 0 ), 66.83 (C-3 0 ), 67.95 (C-7 0 ), 68.68 (C-2 0 ), 71.53 (C-8 0 ), 123.60 (C-5), 140.96 (C-8), 150.22 (C-4), 153.96 (C-2), 168.13 (C-6).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 1 .</head><label>1</label><figDesc>Fig. 1. The general numbering for the assignment of the NMR signals.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>13 C</head><label>13</label><figDesc>NMR (D 2 O þ NaOD, ppm) d: 14.59 (C-23 0 ), 23.22 (C-22 0 ), 26.68 (C-10 0 ), 27.80 (d, J 4 0 eP ¼ 132.1, C-4 0 ), 30.01, 30.17, 30.29, 30.49, 30.54, 30.58, 30.60, 30.63 (C-9 0 , C-11 0 to C-20 0 ), 31.15 (d, J 6 0 eP ¼ 6.3, C-6 0 ), 32.65 (C-21 0 ), 43.38 (C-1 0 ), 61.91 (d, J 5 0 eP ¼ 5.5, C-5 0 ), 66.79 (C- 3 0 ), 67.98 (C-7 0 ), 68.79 (C-2 0 ), 71.56 (C-8 0 ), 117.83 (C-5), 138.91 (C-8), 151.95 (C-4), 160.88 (C-2), 167.82 (C-6).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head></head><label></label><figDesc>Yield 4.60 g (42%). Crystallization from toluene. Mp 180 C. Anal. Calcd for C 34 H 30 N 4 O 3 : C, 75.26; H, 5.57; N, 10.33. Found: C, 75.34; H, 5.62; N, 10.15. 4.4.2. 9-(S)-(2-Hydroxy-3-trityloxypropyl)-2-amino-6-O- benzylpurine (12) Yield 4.89 g (44%). Crystallization from toluene. Mp 177 C, Anal. Calcd for C 34 H 31 N 5 O 3 : C, 73.23; H, 5.60; N, 12.56. Found: C, 73.15; H, 5.62; N, 12.46.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head></head><label></label><figDesc>4.5.1. Bis 3-(hexadecyloxypropyl) ester of 9-(S)-[3-hydroxy-2- (phosphonomethoxy)propyl]hypoxanthine (13) Yield 1.27 g (61%</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head></head><label></label><figDesc>25.43 (C-10 0 ), 28.63e28.96 (m, C-9 0 , C-11 0 to C-20 0 ), 29.97 (d, J 6 0 eP ¼ 6.0, C-6 0 ), 29.98 (d, J 6 0 eP ¼ 6.0, C-6 0 ), 31.21 (C-21 0 ), 43.65 (C- 1 0 ), 59.64 (C-3 0 ), 62.61 (d, J 4 0 eP ¼ 167.6, C-4 0 ), 63.39 (d, J 5 0 eP ¼ 6.7, C- 5 0 ), 63.55 (d, J 5 0 eP ¼ 6.6, C-5 0 ), 65.66, 65.68 (C-7 0 ), 70.48 (C-8 0 ), 80.16 (d, J 2 0 eP ¼ 11.3, C-2 0 ), 123.14 (C-5), 140.79 (C-8), 144.61 (C-2), 148.38 (C-4), 156.85 (C-6).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>13 C</head><label>13</label><figDesc>NMR (CDCl 3 þ MeOD, ppm) d: 13.40 (C-23 0 ), 22.17 (C-22 0 ), 25.64 (C-10 0 ), 28.87e29.20 (m, C-9 0 , C-11 0 to C-20 0 ), 30.22 (d, J 6 0 eP ¼ 5.9, C- 6 0 ), 31.44 (C-21 0 ), 43.07 (C-1 0 ), 59.54 (C-3 0 ), 62.35e63.87 (m, C-4 0 , C- 5 0 ), 65.93 (C-7 0 ), 70.81 (C-8 0 ), 80.66 (d, J 2 0 eP ¼ 10.9, C-2 0 ), 115.00 (C- 5), 138.30 (C-8), 151.09 (C-4), 153.52 (C-2), 157.01 (C-6).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head></head><label></label><figDesc>)propyl]hypoxanthine (15) Yield: 237 mg (81%). Mp 199e202 C. ESI-MS, m/z: 585.d: 14.47 (C-23 0 ), 23.22 (C-22 0 ), 26.61 (C-10 0 ), 29.97e30.55 (m, C-9 0 , C-11 0 to C-20 0 ), 31.22 (C-6 0 ), 32.54 (C-21 0 ), 44.28 (C-1 0 ), 60.87 (C-3 0 ), 62.80 (d, J 5 0 eP ¼ 5.3, C-5 0 ), 65.67 (d, J 4 0 eP ¼ 158.0, C-4 0 ), 67.91 (C-7 0 ), 71.52 (C-8 0 ), 80.98 (d, J 2 0 eP ¼ 11.8, C-2 0 ), 123.44 (C-5), 141.38 (C-8), 150.39 (C-4), 154.03 (C-2), 168.18 (C-6). 4.6.2. 3-(Hexadecyloxypropyl) ester of 9-(S)-[3-hydroxy-2- (phosphonomethoxy)propyl]guanine (16) Yield 265 mg (88%). Mp 235e238 C. Anal. Calcd for C 28 H 54 N 5 O 8 P (monohydrate): C, 54.27; H, 8.78; N,11.30; P, 5.00. Found: C, 54.16; H,</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0" validated="false"><head>Table 1</head><label>1</label><figDesc>Antiviral and cytotoxic/static activity of the compounds against herpesviruses and poxviruses in cell culture. Compounds Antiviral activity: EC 50 (mM) in HEL (human embryonic lung) fibroblasts except for feline herpesvirus and selectivity indexes (in bold italics)</figDesc><table>Cytotoxicity in HEL cells 
(mM) 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6" validated="false"><head></head><label></label><figDesc>). Mp 86 C. Anal. Calcd for C 47 H 89 N 4 O 8 P: C, 64.95; H, 10.32; N, 6.45; P, 3.56. Found: C, 64.99; H, 10.42; N, 6.44; P, 3.73; ESI-MS, m/z: 869.6 (24) [M þ H] þ , 891.7 (100) [M þ Na] þ . ESI-HRMS calcd for C 47 H 90 N 4 O 8 P 869.6491, found: 869.6490 [M þ H]; calcd for C 47 H 89 N 4 O 8 PNa 891.6310, found: 891.6311 [M þ Na] þ .</figDesc><table>þ 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7" validated="false"><head></head><label></label><figDesc>32%). Mp 166e168 C. Anal. Calcd for C 47 H 92 N 5 O 9 P (monohydrate): C, 62.57; H, 10.28; N, 7.76; P, 3.43. Found: C, 62.79; H, 10.18; N, 7.69; P, 3.41. ESI-MS, m/z: 301.1 (68), 884.6 (61) [M þ H] þ , 906.7 (100) [M þ Na] þ . ESI-HRMS calcd for C 47 H 91 N 5 O 8 P 884.6600, found: 884.6606 [M þ H] þ ; calcd for C 47 H 90 N 5 O 8 PNa 906.6419, found: 906.6425 [M þ Na] þ . 1 H NMR (CDCl 3 þ MeOD, ppm) d: 0.85 (m, 6H, H-23 0 ), 1.18e1.32 (m, 52H, H-10 0 to H-22 0 ), 1.52 (m, 4H, H-9 0 ), 1.89 (m, 4H, H-6 0 ), 3.38 (m, 4H, H-8 0 ), 3.47 (m, 4H, H- 7 0 ), 3.56 (m, 2H, H-3 0 ), 3.76 (m, 1H, H-2 0 ), 3.85e3.96 (m, 2H, H-4 0 ), 4.10e4.18 (m, 5H, H-1 0 b, H-5 0 ), 4.25 (m, 1H, H-1 0 a), 7.74 (s, 1H, H-8).</figDesc><table>4.5.2. Bis 3-(hexadecyloxypropyl) ester of 9-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]guanine (14) 
Yield 0.68 g (</table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1">H NMR (CDCl 3 þ MeOD, ppm) d: 0.89 (t, 6H, J 23 0 e22 0 ¼ 7.0, H-23 0 ), 1.23e1.35 (m, 52H, H-10 0 to H-22 0 ), 1.56 (m, 4H, H-9 0 ), 1.92 (m, 4H, H-6 0 ), 3.42 (m, 4H, H-7 0 ), 3.50 (m, 4H, H-8 0 ), 3.61 (dd, 1H, J gem ¼ 12.3, J 3 0 e2 0 ¼ 4.7, H-3 0 b), 3.69 (dd, 1H, J gem ¼ 12.3, J 3 0 e2 0 ¼ 4.8, H-3 0 a), 3.87 (m, 1H, H-2 0 ), 3.89 (dd, 1H, J gem ¼ 13.8, J 4 0 eP ¼ 9.1, H-4 0 b), 4.01 (dd, 1H, J gem ¼ 13.8, J 4 0 eP ¼ 8.9, H-4 0 a), 4.10e4.18 (m, 4H, H-5 0 ), 4.37 (dd, 1H, J gem ¼ 14.6, J 1 0 e2 0 ¼ 7.0, H-1 0 b), 4.49 (dd, J gem ¼ 14.6, J 1 0 e2 0 ¼ 4.0, H-1 0 a), 8.00 (s, 1H, H-2), 8.04 (s, 1H, H-8). 13 C NMR (CDCl 3 þ MeOD, ppm) d: 12.97 (C-23 0 ), 21.91 (C-22 0 ),</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"> <ref type="bibr" target="#b12">13</ref> </div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.">General method G</head><p>Hünig's base (0.4 mmol, 70 ml) was added to a mixture of 15 or 16 (0.2 mmol, 117 mg or 120 mg respectively), PyBOP (0.4 mmol, 208 mg) in DMF (1 ml). The suspension was sonicated until it dissolved and then kept at room temperature overnight. The mixture was evaporated and the syrupy residue was chromatographed on a silica gel column (50 g) in 12% MeOH/CHCl 3 . The product was crystallized from methanol.     </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.7.2.">3-(Hexadecyloxypropyl</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.8.">Antiviral activity assays</head><p>The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinase- </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.9.">Cytotoxicity assays</head><p>Cytotoxicity measurements were based on the inhibition of cell growth. HEL cells were seeded at a rate of 5 Â 10 3 cells/well into 96-well microtiter plates and allowed to adhere and proliferate for 24 h. Then, medium containing different concentrations of the test compounds was added. After 3 days of further incubation at 37 C, the cell number was determined with a Coulter counter. The cytostatic concentration was calculated as the CC 50 , or the compound concentration required reducing cell proliferation by 50% relative to the number of cells in the untreated controls. CC 50 values were estimated from graphic plots of the number of cells (percentage of control) as a function of the concentration of the test compounds. Alternatively, cytotoxicity of the test compounds was expressed as the minimum cytotoxic concentration (MCC) or the compound concentration that caused a microscopically detectable alteration of cell morphology. Selectivity indexes were calculated as the ratio CC 50 to EC 50 .</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">De</forename><surname>Clercq</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">T</forename><surname>Keough</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hocková</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holý</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Naesens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">S</forename><surname>Skinner-Adams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>De Jersey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Guddat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page">4391</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>De Jersey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hockova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Naesens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">T</forename><surname>Keough</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">W</forename><surname>Guddat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Top. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">2085</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Hostetler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page">84</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hockova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Tichy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">T</forename><surname>Keough</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Naesens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">S</forename><surname>Skinner-Adams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>De Jersey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Guddat</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>unpublished results</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>De Clercq</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Sakuma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Pauwels</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Balzarini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holý</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">261</biblScope>
			<date type="published" when="1987" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Valiaeva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">N</forename><surname>Prichard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Buller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Hartline</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Keith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Schriewer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Trahan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Hostetler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page">254</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Starrett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">R</forename><surname>Tortolani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J M</forename><surname>Hitchcock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Whiterock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Mansuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">1857</biblScope>
			<date type="published" when="1994" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Tichý</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Andrei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Dra Cínský</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holý</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Balzarini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Snoeck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Cmerová</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">3527</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Jansa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holý</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Dra Cinský</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Baszczy Nski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Cesnek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Janeba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Green Chem</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">882</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holý</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synthesis</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">381</biblScope>
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Vrbkova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Dra Cínský</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Holý</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tetrahedron</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page">11391</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Campagne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Coste</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Jouin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Org. Chem</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page">5214</biblScope>
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hartline</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Aldern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Harden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">R</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Hostetler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob. Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page">2381</biblScope>
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">B</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Ciesla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Keith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hartline</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">R</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Hostetler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page">2010</biblScope>
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
